Immune interventions in HIV infection

Authors

  • Guislaine Carcelain,

    1. UPMC Univ Paris 06, UMR-S945, Laboratory of Immunity and Infection, Paris, France
    2. Inserm, U945, Laboratory of Immunity and Infection, Paris, France
    3. AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France
    Search for more papers by this author
  • Brigitte Autran

    Corresponding author
    1. Inserm, U945, Laboratory of Immunity and Infection, Paris, France
    2. AP-HP, Hôpital Pitié-Salpêtrière, Département d'Immunologie, Paris, France
    • UPMC Univ Paris 06, UMR-S945, Laboratory of Immunity and Infection, Paris, France
    Search for more papers by this author

Correspondence to:

Briggite Autran

Département d'Immunologie, AP-HP

INSERM UMR S-945/UPMC Paris VI

Hôpital Pitié-Salpêtrière

Bâtiment CERVI 4ème étage

83 Bd de l'Hôpital

Paris, Cedex 13 75651, France

Tel.: +33 1 42 17 74 03

Fax: +33 1 42 17 74 90

e-mail: brigitte.autran@psl.aphp.fr

Summary

Immune-based therapy (IBT) interventions have found a window of opportunity within some limitations of the otherwise successful combined antiretroviral therapy (cART). Two major paradigms drove immunotherapeutic research to combat human immunodeficiency virus (HIV) infection. First, IBTs were proposed either to help restore CD4+ T-cell counts in cases of therapeutic failures with cytokines, interleukin-2 (IL-2) or IL-7, or to better control HIV and disease progression during treatment interruptions with anti-HIV therapeutic candidate vaccines. The most widely used candidates were HIV-recombinant live vector-based alone or combined with other vaccine compounds and dendritic cell (DC) therapies. A more recent and current paradigm aims at achieving HIV cure by combining IBT with cART using either cytokines to reactivate virus production in latently infected cells and/or therapeutic immunization to boost HIV-specific immunity in a ‘shock and kill’ strategy. This review summarizes the rationale, hopes, and mechanisms of successes and failures of these cytokine-based and vaccine-based immune interventions. Results from these first series of IBTs have been so far somewhat disappointing in terms of clinical relevance, but have provided lessons that are discussed in light of the future combined strategies to be developed toward an HIV cure.

Ancillary